5% Hydroquinone with Non-ablative fractional 1540 Erbium YAG Laser in the Treatment of Melasma

Comparison combination of hydroquinon 5% with laser Non-ablative fractional 1540 erbium YAG versus hydroquinon 5% in treatment of melasma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061727097N3

Enrollment

Registered

2017-07-18

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. Chloasma

Interventions

Intervention 1: Case group: non-ablative fractional 1540 erbium YAG laser. Intervention 2: Control group: 5% hydroquinone, solution, Topical, twice a day for five month.

Treatment - Other

Treatment - Drugs

Case group: non-ablative fractional 1540 erbium YAG laser

Control group: 5% hydroquinone, solution, Topical, twice a day for five month

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with moderate to severe melasma; patients with type 2 to 4 Fitzpatrick moderate to severe melasma, patients with mental health who are able to give information in the research process; patients with their complete satisfaction to participate in the study. Exclusion criteria: patients with dermatitis in the place; Patients with unrealistic demands and expectations of treatment; Patients taking isotretinoin in the last 6 months; pregnant women; patients with a history of keloid; lactating women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pigmentation. Timepoint: Before the study, Five months after the study. Method of measurement: Clinical examination.	—

Secondary

Measure	Time frame
Complications. Timepoint: Before the study, Five months after the study. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sanay Azizifard

Tabriz University of Medical Sceinces

Aaf_azizifard@yahoo.com+98 41 3336 4667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026